Pub Date : 2024-02-06DOI: 10.15406/htij.2024.12.00323
Bahram Alamdary Badlou
Background: The speed of the COVID-19 pandemic, and its potential threat to society, achieved through strange global collaborations and innovation between clinical specialties, different elite research organizations, academic institutions, and governments, recently. Cancer clinical trials have developed into a diverse and sophisticated array of designs suited to differing purposes especially focused on excess accelerated mortality rates between patients. Understanding the mechanism of bidirectional interaction between different angles of the death triangle is a lifesaving novel idea that I conceived from 2018. On one hand, platelet dysfunction after certain pharmaco-toxicological approaches in diabetes, and cancer patients; and on the other hand intervention of different COVID-19 variants, mutating each month, caused (hypothetically) remarkable acceleration of introduced angels of death triangle machinery. A considerable concern is modification of medical sciences using AI-related data processing and manipulations into substantial changes of background information presentation. Discussion: Different study groups describe how different microorganisms might be involved in accelerated mortality and morbidity rate among diabetes and cancer patients, in this postcovid-19 era. There are different theories about cancerogenic processes and associated accelerating factors. Simultaneously, restrictions by certain main Policymakers made mission impossible to tackle excess accelerated increase in mortality and morbidity rates, between2021-2024. How death receptors become activated and could accelerate harmful processes is not completely elucidated yet. Based on recent studies diabetic and cancerogenic processes can initiate susceptibility to getting infected, however. Lack of a golden standard protocol to prevent blood transfusion-based infection and Transplantation-based transfections, also brought certain (re-)actions of Basic Scientists entirely in a cloudy atmosphere, where more questions than answers appeared to need being answered from 2019. In this paper is tried to highlight more about consequent (re-)action and (ab)using diagnostics that can support using a certain type of therapeutics, which they might cause excess accelerated mortality rates, in these cloudy uncertain post-Covid-19 era.
{"title":"POSTCOVID-19 WAR era, remarkable accelerated hemato-immunologic processes affecting patients disease progression toward excess mortality","authors":"Bahram Alamdary Badlou","doi":"10.15406/htij.2024.12.00323","DOIUrl":"https://doi.org/10.15406/htij.2024.12.00323","url":null,"abstract":"Background: The speed of the COVID-19 pandemic, and its potential threat to society, achieved through strange global collaborations and innovation between clinical specialties, different elite research organizations, academic institutions, and governments, recently. Cancer clinical trials have developed into a diverse and sophisticated array of designs suited to differing purposes especially focused on excess accelerated mortality rates between patients. Understanding the mechanism of bidirectional interaction between different angles of the death triangle is a lifesaving novel idea that I conceived from 2018. On one hand, platelet dysfunction after certain pharmaco-toxicological approaches in diabetes, and cancer patients; and on the other hand intervention of different COVID-19 variants, mutating each month, caused (hypothetically) remarkable acceleration of introduced angels of death triangle machinery. A considerable concern is modification of medical sciences using AI-related data processing and manipulations into substantial changes of background information presentation. Discussion: Different study groups describe how different microorganisms might be involved in accelerated mortality and morbidity rate among diabetes and cancer patients, in this postcovid-19 era. There are different theories about cancerogenic processes and associated accelerating factors. Simultaneously, restrictions by certain main Policymakers made mission impossible to tackle excess accelerated increase in mortality and morbidity rates, between2021-2024. How death receptors become activated and could accelerate harmful processes is not completely elucidated yet. Based on recent studies diabetic and cancerogenic processes can initiate susceptibility to getting infected, however. Lack of a golden standard protocol to prevent blood transfusion-based infection and Transplantation-based transfections, also brought certain (re-)actions of Basic Scientists entirely in a cloudy atmosphere, where more questions than answers appeared to need being answered from 2019. In this paper is tried to highlight more about consequent (re-)action and (ab)using diagnostics that can support using a certain type of therapeutics, which they might cause excess accelerated mortality rates, in these cloudy uncertain post-Covid-19 era.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"28 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139862508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-06DOI: 10.15406/htij.2024.12.00323
Bahram Alamdary Badlou
Background: The speed of the COVID-19 pandemic, and its potential threat to society, achieved through strange global collaborations and innovation between clinical specialties, different elite research organizations, academic institutions, and governments, recently. Cancer clinical trials have developed into a diverse and sophisticated array of designs suited to differing purposes especially focused on excess accelerated mortality rates between patients. Understanding the mechanism of bidirectional interaction between different angles of the death triangle is a lifesaving novel idea that I conceived from 2018. On one hand, platelet dysfunction after certain pharmaco-toxicological approaches in diabetes, and cancer patients; and on the other hand intervention of different COVID-19 variants, mutating each month, caused (hypothetically) remarkable acceleration of introduced angels of death triangle machinery. A considerable concern is modification of medical sciences using AI-related data processing and manipulations into substantial changes of background information presentation. Discussion: Different study groups describe how different microorganisms might be involved in accelerated mortality and morbidity rate among diabetes and cancer patients, in this postcovid-19 era. There are different theories about cancerogenic processes and associated accelerating factors. Simultaneously, restrictions by certain main Policymakers made mission impossible to tackle excess accelerated increase in mortality and morbidity rates, between2021-2024. How death receptors become activated and could accelerate harmful processes is not completely elucidated yet. Based on recent studies diabetic and cancerogenic processes can initiate susceptibility to getting infected, however. Lack of a golden standard protocol to prevent blood transfusion-based infection and Transplantation-based transfections, also brought certain (re-)actions of Basic Scientists entirely in a cloudy atmosphere, where more questions than answers appeared to need being answered from 2019. In this paper is tried to highlight more about consequent (re-)action and (ab)using diagnostics that can support using a certain type of therapeutics, which they might cause excess accelerated mortality rates, in these cloudy uncertain post-Covid-19 era.
{"title":"POSTCOVID-19 WAR era, remarkable accelerated hemato-immunologic processes affecting patients disease progression toward excess mortality","authors":"Bahram Alamdary Badlou","doi":"10.15406/htij.2024.12.00323","DOIUrl":"https://doi.org/10.15406/htij.2024.12.00323","url":null,"abstract":"Background: The speed of the COVID-19 pandemic, and its potential threat to society, achieved through strange global collaborations and innovation between clinical specialties, different elite research organizations, academic institutions, and governments, recently. Cancer clinical trials have developed into a diverse and sophisticated array of designs suited to differing purposes especially focused on excess accelerated mortality rates between patients. Understanding the mechanism of bidirectional interaction between different angles of the death triangle is a lifesaving novel idea that I conceived from 2018. On one hand, platelet dysfunction after certain pharmaco-toxicological approaches in diabetes, and cancer patients; and on the other hand intervention of different COVID-19 variants, mutating each month, caused (hypothetically) remarkable acceleration of introduced angels of death triangle machinery. A considerable concern is modification of medical sciences using AI-related data processing and manipulations into substantial changes of background information presentation. Discussion: Different study groups describe how different microorganisms might be involved in accelerated mortality and morbidity rate among diabetes and cancer patients, in this postcovid-19 era. There are different theories about cancerogenic processes and associated accelerating factors. Simultaneously, restrictions by certain main Policymakers made mission impossible to tackle excess accelerated increase in mortality and morbidity rates, between2021-2024. How death receptors become activated and could accelerate harmful processes is not completely elucidated yet. Based on recent studies diabetic and cancerogenic processes can initiate susceptibility to getting infected, however. Lack of a golden standard protocol to prevent blood transfusion-based infection and Transplantation-based transfections, also brought certain (re-)actions of Basic Scientists entirely in a cloudy atmosphere, where more questions than answers appeared to need being answered from 2019. In this paper is tried to highlight more about consequent (re-)action and (ab)using diagnostics that can support using a certain type of therapeutics, which they might cause excess accelerated mortality rates, in these cloudy uncertain post-Covid-19 era.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"58 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139802440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Von Willebrand diseases is a hereditary bleeding disorder caused by a quantitative or qualitative deficiency of von Willebrand factor, characterized by light mucocutaneous bleeding, although other bleeding such as gastrointestinal and joint bleeding may occur in severely affected patients. It treatment is fundamentally based on replacement therapy and the use of desmoprecin. Objective: Describe the characteristics and clinical evolution of a patient who presented upper gastrointestinal bleeding as a form of presentation of von Willebrand disease. Conclusions: von Willebrand diseases hould be suspected in patients with abnormal bleeding symptoms without apparent causes.
{"title":"Von willebrand disease and gastrointestinal bleeding: case presentation","authors":"Ariel Raúl Aragón Abrantes, Danelis Hernández Aguiar, Nidia Crespo Toledo, Carmen Ulloa Olivera","doi":"10.15406/htij.2024.12.00322","DOIUrl":"https://doi.org/10.15406/htij.2024.12.00322","url":null,"abstract":"Introduction: Von Willebrand diseases is a hereditary bleeding disorder caused by a quantitative or qualitative deficiency of von Willebrand factor, characterized by light mucocutaneous bleeding, although other bleeding such as gastrointestinal and joint bleeding may occur in severely affected patients. It treatment is fundamentally based on replacement therapy and the use of desmoprecin. Objective: Describe the characteristics and clinical evolution of a patient who presented upper gastrointestinal bleeding as a form of presentation of von Willebrand disease. Conclusions: von Willebrand diseases hould be suspected in patients with abnormal bleeding symptoms without apparent causes.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"92 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139832159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Von Willebrand diseases is a hereditary bleeding disorder caused by a quantitative or qualitative deficiency of von Willebrand factor, characterized by light mucocutaneous bleeding, although other bleeding such as gastrointestinal and joint bleeding may occur in severely affected patients. It treatment is fundamentally based on replacement therapy and the use of desmoprecin. Objective: Describe the characteristics and clinical evolution of a patient who presented upper gastrointestinal bleeding as a form of presentation of von Willebrand disease. Conclusions: von Willebrand diseases hould be suspected in patients with abnormal bleeding symptoms without apparent causes.
{"title":"Von willebrand disease and gastrointestinal bleeding: case presentation","authors":"Ariel Raúl Aragón Abrantes, Danelis Hernández Aguiar, Nidia Crespo Toledo, Carmen Ulloa Olivera","doi":"10.15406/htij.2024.12.00322","DOIUrl":"https://doi.org/10.15406/htij.2024.12.00322","url":null,"abstract":"Introduction: Von Willebrand diseases is a hereditary bleeding disorder caused by a quantitative or qualitative deficiency of von Willebrand factor, characterized by light mucocutaneous bleeding, although other bleeding such as gastrointestinal and joint bleeding may occur in severely affected patients. It treatment is fundamentally based on replacement therapy and the use of desmoprecin. Objective: Describe the characteristics and clinical evolution of a patient who presented upper gastrointestinal bleeding as a form of presentation of von Willebrand disease. Conclusions: von Willebrand diseases hould be suspected in patients with abnormal bleeding symptoms without apparent causes.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"8 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139892062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-02DOI: 10.15406/htij.2024.12.00320
Niman Tayib, Gebeyaw Arega, Girum Tesfaye, Abdi Hasan, W. Adissu
Background: As anemia is a prevalent condition in geriatrics and old age and its frequency proportionately increases with age, leading to severe consequences; any magnitude of it is now recognized as a risk factor for any adverse outcomes: decreased quality-of-life, hospitalization, morbidity, and mortality. Despite its clinical importance, the problem is not widely recognized. Therefore, regular surveillance could provide evidence-based local data required for interventions. This study is aimed to assess the prevalence and associated factors of anemia among elderly patients in eastern Ethiopia. Methods: From June 20 to July 30, 2022, a cross-sectional study centered in an institution was carried out, enrolling 381 elderly patients. Direct interviewing and review of medical records were used to gather socio-demographic and clinical data. Each participant provided a venous blood sample to determine total blood cell count and blood peripheral film examination; to identify hemoparasites and the morphological type of anemia. Using SPSS version 25, descriptive statistical analysis and bivariate and multivariate logistic regressions were used, and statistical significance was set at p<0.05. Result: Anemia was seen in 40.4% of participants, mild, moderate, and severe anemia accounts for 71.1%, 23.1%, and 5.8%, respectively. Normocytic normochromic anemia was seen in 55.13% of cases, and microcytic hypochromic in 37.18%. The anemia was substantially correlated with being male [AOR=0.352 95% CI: 0.174, 0.708], having a lower socioeconomic status [AOR=0.041 95% CI: 0.011, 0.156], and eating meat less than once per week [AOR=0.301 95% CI: 0.114, 0.793]. Conclusion and recommendation: The prevalence of anemia among elderly patients in this area was found to be a severe public health problem. Mild anemia was the predominant type. Identified risk factors should be considered to prevent and control anemia, and screening for anemia among the elderly should be a part of their routine management.
{"title":"Prevalence and associated factors of anemia among elderly patients at a tertiary hospital in Estern Ethiopia: a cross-sectional study","authors":"Niman Tayib, Gebeyaw Arega, Girum Tesfaye, Abdi Hasan, W. Adissu","doi":"10.15406/htij.2024.12.00320","DOIUrl":"https://doi.org/10.15406/htij.2024.12.00320","url":null,"abstract":"Background: As anemia is a prevalent condition in geriatrics and old age and its frequency proportionately increases with age, leading to severe consequences; any magnitude of it is now recognized as a risk factor for any adverse outcomes: decreased quality-of-life, hospitalization, morbidity, and mortality. Despite its clinical importance, the problem is not widely recognized. Therefore, regular surveillance could provide evidence-based local data required for interventions. This study is aimed to assess the prevalence and associated factors of anemia among elderly patients in eastern Ethiopia. Methods: From June 20 to July 30, 2022, a cross-sectional study centered in an institution was carried out, enrolling 381 elderly patients. Direct interviewing and review of medical records were used to gather socio-demographic and clinical data. Each participant provided a venous blood sample to determine total blood cell count and blood peripheral film examination; to identify hemoparasites and the morphological type of anemia. Using SPSS version 25, descriptive statistical analysis and bivariate and multivariate logistic regressions were used, and statistical significance was set at p<0.05. Result: Anemia was seen in 40.4% of participants, mild, moderate, and severe anemia accounts for 71.1%, 23.1%, and 5.8%, respectively. Normocytic normochromic anemia was seen in 55.13% of cases, and microcytic hypochromic in 37.18%. The anemia was substantially correlated with being male [AOR=0.352 95% CI: 0.174, 0.708], having a lower socioeconomic status [AOR=0.041 95% CI: 0.011, 0.156], and eating meat less than once per week [AOR=0.301 95% CI: 0.114, 0.793]. Conclusion and recommendation: The prevalence of anemia among elderly patients in this area was found to be a severe public health problem. Mild anemia was the predominant type. Identified risk factors should be considered to prevent and control anemia, and screening for anemia among the elderly should be a part of their routine management.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"7 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139452635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-18DOI: 10.15406/htij.2023.11.00318
Gallardo Navarro Elias, Adriana Margarita Acosta Blanco, Mancera Steiner Carlos, Francisco García Rodríguez
Currently, squamous vulvar cancer is rare, which is why there is limited experience among health personnel in recognizing and managing this type of tumor location. The purpose of this case is to present the case of an 87-year-old woman with an ulcerative lesion on the vulva who underwent left vulvectomy with a report of squamous cell carcinoma in situ pathology, with favorable post-surgical evolution and without the need for adjuvant treatment when the inguinal lymph node was negative for metastasis.
{"title":"Squamous cell carcinoma in situ of the vulva","authors":"Gallardo Navarro Elias, Adriana Margarita Acosta Blanco, Mancera Steiner Carlos, Francisco García Rodríguez","doi":"10.15406/htij.2023.11.00318","DOIUrl":"https://doi.org/10.15406/htij.2023.11.00318","url":null,"abstract":"Currently, squamous vulvar cancer is rare, which is why there is limited experience among health personnel in recognizing and managing this type of tumor location. The purpose of this case is to present the case of an 87-year-old woman with an ulcerative lesion on the vulva who underwent left vulvectomy with a report of squamous cell carcinoma in situ pathology, with favorable post-surgical evolution and without the need for adjuvant treatment when the inguinal lymph node was negative for metastasis.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"111 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138965068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-13DOI: 10.15406/htij.2023.11.00317
Gallardo Navarro Elias, García Rodríguez Francisco, Mancera Steiner Carlos
Renal oncocytosis is a rare disorder in which numerous oncocytic nodules develop in the kidney. It is a benign tumor that is occasionally discovered incidentally when performing an imaging test for other reasons. The clinical case of a patient who presented hematuria of 6 months of evolution is presented. After complementary studies, a right renal mass was discovered, for which he underwent radical nephrectomy, with histological result of carcinoma with an oncocytic appearance compatible with chromophobe carcinoma. He presented in the emergency department 3 months after surgery, presenting with anuria accompanied by renal failure. Imaging studies were again requested and a mass dependence on the left kidney was observed. The same surgical procedure was performed and histopathological study demonstrated that the lesion removed corresponded to oncocytosis. Both kidneys are evaluated with immunohistochemistry, being definitive of bilateral renal oncocytosis.
{"title":"Bilateral renal oncocytosis treated by nephrectomy","authors":"Gallardo Navarro Elias, García Rodríguez Francisco, Mancera Steiner Carlos","doi":"10.15406/htij.2023.11.00317","DOIUrl":"https://doi.org/10.15406/htij.2023.11.00317","url":null,"abstract":"Renal oncocytosis is a rare disorder in which numerous oncocytic nodules develop in the kidney. It is a benign tumor that is occasionally discovered incidentally when performing an imaging test for other reasons. The clinical case of a patient who presented hematuria of 6 months of evolution is presented. After complementary studies, a right renal mass was discovered, for which he underwent radical nephrectomy, with histological result of carcinoma with an oncocytic appearance compatible with chromophobe carcinoma. He presented in the emergency department 3 months after surgery, presenting with anuria accompanied by renal failure. Imaging studies were again requested and a mass dependence on the left kidney was observed. The same surgical procedure was performed and histopathological study demonstrated that the lesion removed corresponded to oncocytosis. Both kidneys are evaluated with immunohistochemistry, being definitive of bilateral renal oncocytosis.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"24 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139005178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-03DOI: 10.15406/htij.2023.11.00310
Ariel Raúl Aragón Abrantes
Introduction: Fanconi Anemia is a congenital disease associated with defects in the mechanisms of repair of the genetic material that allow to maintain the stability of the human genoma. Paroxysmal Nocturnal Hemoglobinuria is a clonal and acquired disease caused by a somatic mutation in the gene PIG-A. Objective: to present the characteristics of a child with diagnosis of Fanconi Anemia with a Paroxysmal Nocturnal Hemoglobinuria clone. Development: An 8 year-old female infant who come to the consultation for mucosal-skin paleness and purpuric manifestations. After several studies the diagnosis of Fanconi Anemia with Paroxysmal Nocturnal Hemoglobinuria clone was made. Conclusions: patient with a medullary failure congenital and acquired, that given their characteristics require of the bone marrow transplantation like only curative therapy.
{"title":"Fanconi anemia and paroxysmal nocturnal hemoglobinuria, case report","authors":"Ariel Raúl Aragón Abrantes","doi":"10.15406/htij.2023.11.00310","DOIUrl":"https://doi.org/10.15406/htij.2023.11.00310","url":null,"abstract":"Introduction: Fanconi Anemia is a congenital disease associated with defects in the mechanisms of repair of the genetic material that allow to maintain the stability of the human genoma. Paroxysmal Nocturnal Hemoglobinuria is a clonal and acquired disease caused by a somatic mutation in the gene PIG-A. Objective: to present the characteristics of a child with diagnosis of Fanconi Anemia with a Paroxysmal Nocturnal Hemoglobinuria clone. Development: An 8 year-old female infant who come to the consultation for mucosal-skin paleness and purpuric manifestations. After several studies the diagnosis of Fanconi Anemia with Paroxysmal Nocturnal Hemoglobinuria clone was made. Conclusions: patient with a medullary failure congenital and acquired, that given their characteristics require of the bone marrow transplantation like only curative therapy.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133381017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-28DOI: 10.15406/htij.2023.11.00308
Dmitriev Vv, Begun Iv, Borisenok Mb
Objective: evaluate the pharmacokinetics and pharmacodynamics of nadroparin and dalteparin in thrombosis that occurred in children with malignant neoplasms. Materials and methods: The results of 52 pharmacokinetic studies involving 34 patients with oncological diseases, whose treatment was complicated by venous thrombosis, were analyzed. The median age of patients was 14.5 (7–18) years. Depending on the daily dose and the type of heparin administered, the results of pharmacokinetic studies were divided into 6 groups. Dalteparin sodium: against the background of chemo-induced thrombocytopenia, subcutaneous administration of dalteparin at a dose of 51.0 (40.0–72.0) anti-Xa IU/kg every 12 hours – 6 observations; subcutaneous injection every 12 hours at a dose of 100.5 (91.0–141.0) anti-Xa IU/kg – 18 observations; long-term continuous intravenous infusion at a constant rate at a daily dose of 201.0 (180.0–265.0) anti-Xa IU/kg - 6 observations. Nadroparin calcium: 62.0 (53.0-71.0) anti-Xa IU/kg every 12 hours - 6 observations; 93.5 (80.0–117.0) anti-Xa IU/kg every 12 hours – 10 observations; subcutaneous injection at a dose of 203.0 (170.0–236.0) anti-Xa IU/kg once a day - 6 observations. Results: We confirmed that in the acute period of thrombosis in children, the most optimal way to administer low molecular weight heparin is intravenous infusion of dalteparin sodium at a constant rate. Subcutaneous injection of 50% of the daily dose of LMWH at intervals of 12 hours is preferable to a single injection of 100% of the daily dose every 24 hours. There were no significant advantages of nadroparin compared with dalteparin when using anticoagulants in comparable doses in case of venous thrombosis, which complicated the treatment of children with malignant neoplasms. Conclusion: Control over the adequacy of the dose of LMWH can be performed at any stage of treatment. The specific anti-Xa activity of nadroparin and dalteparin needs to be checked before the next subcutaneous injection and between 3 and 4 hours after administration. An increase in chronometric indicators of blood coagulation indirectly reflects the presence of an anticoagulant in the blood, but does not allow an objective assessment of the achievement of a therapeutic effect.
目的:评价纳德帕林和达特帕林在儿童恶性肿瘤血栓形成中的药代动力学和药效学。材料与方法:对34例合并静脉血栓形成的肿瘤疾病患者52项药代动力学研究结果进行分析。患者中位年龄为14.5(7-18)岁。根据给药肝素的日剂量和类型，将药代动力学研究结果分为6组。达达哌林钠:在化疗引起的血小板减少的背景下，每12小时皮下给药51.0(40.0-72.0)抗xa IU/kg - 6次观察;每12小时皮下注射一次，剂量为100.5(91.0-141.0)抗xa IU/kg - 18次观察;长期静脉持续等速滴注，日剂量201.0(180.0-265.0)抗- xa IU/kg。钠红素钙:62.0(53.0-71.0)抗- xa IU/kg每12小时- 6次观察;每12小时93.5(80.0-117.0)抗- xa IU/kg - 10次观察;皮下注射203.0(170.0-236.0)抗- xa IU/kg，每日1次- 6次观察。结果:我们证实，在儿童血栓形成急性期，低分子肝素的最佳给药方式是恒速静脉滴注达他帕林钠。每隔12小时皮下注射低分子肝素每日剂量的50%比每24小时单次注射每日剂量的100%更可取。静脉血栓形成使儿童恶性肿瘤的治疗复杂化，在同等剂量下使用抗凝剂时，nadroparin与dalteparin相比没有明显优势。结论:在治疗的任何阶段都可以对低分子肝素剂量的适当性进行控制。nadroparin和dalteparin的特异性抗xa活性需要在下一次皮下注射前和给药后3 - 4小时检查。血液凝固时间指标的增加间接反映了血液中抗凝剂的存在，但不能客观地评价治疗效果的实现。
{"title":"Pharmacokinetics of dalteparin and nadroparin for thromboses in children with oncological diseases","authors":"Dmitriev Vv, Begun Iv, Borisenok Mb","doi":"10.15406/htij.2023.11.00308","DOIUrl":"https://doi.org/10.15406/htij.2023.11.00308","url":null,"abstract":"Objective: evaluate the pharmacokinetics and pharmacodynamics of nadroparin and dalteparin in thrombosis that occurred in children with malignant neoplasms. Materials and methods: The results of 52 pharmacokinetic studies involving 34 patients with oncological diseases, whose treatment was complicated by venous thrombosis, were analyzed. The median age of patients was 14.5 (7–18) years. Depending on the daily dose and the type of heparin administered, the results of pharmacokinetic studies were divided into 6 groups. Dalteparin sodium: against the background of chemo-induced thrombocytopenia, subcutaneous administration of dalteparin at a dose of 51.0 (40.0–72.0) anti-Xa IU/kg every 12 hours – 6 observations; subcutaneous injection every 12 hours at a dose of 100.5 (91.0–141.0) anti-Xa IU/kg – 18 observations; long-term continuous intravenous infusion at a constant rate at a daily dose of 201.0 (180.0–265.0) anti-Xa IU/kg - 6 observations. Nadroparin calcium: 62.0 (53.0-71.0) anti-Xa IU/kg every 12 hours - 6 observations; 93.5 (80.0–117.0) anti-Xa IU/kg every 12 hours – 10 observations; subcutaneous injection at a dose of 203.0 (170.0–236.0) anti-Xa IU/kg once a day - 6 observations. Results: We confirmed that in the acute period of thrombosis in children, the most optimal way to administer low molecular weight heparin is intravenous infusion of dalteparin sodium at a constant rate. Subcutaneous injection of 50% of the daily dose of LMWH at intervals of 12 hours is preferable to a single injection of 100% of the daily dose every 24 hours. There were no significant advantages of nadroparin compared with dalteparin when using anticoagulants in comparable doses in case of venous thrombosis, which complicated the treatment of children with malignant neoplasms. Conclusion: Control over the adequacy of the dose of LMWH can be performed at any stage of treatment. The specific anti-Xa activity of nadroparin and dalteparin needs to be checked before the next subcutaneous injection and between 3 and 4 hours after administration. An increase in chronometric indicators of blood coagulation indirectly reflects the presence of an anticoagulant in the blood, but does not allow an objective assessment of the achievement of a therapeutic effect.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130793585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-12DOI: 10.15406/htij.2023.11.00307
Anu Bajaj
Striated duct adenoma is an exceptionally encountered, benign salivary gland neoplasm. Tumefaction is constituted of ductal articulations coated with mono-layered epithelial cells and a cytological resemblance to normal striated ducts. Striated duct adenoma may recapitulates normal configuration of salivary ducts. Striated duct adenoma was initially scripted by Dardick wherein the neoplasm was designated as ‘ductal adenomas with no visible myoepithelial cells’ in 1996.
{"title":"The convoluted conduit-striated duct adenoma","authors":"Anu Bajaj","doi":"10.15406/htij.2023.11.00307","DOIUrl":"https://doi.org/10.15406/htij.2023.11.00307","url":null,"abstract":"Striated duct adenoma is an exceptionally encountered, benign salivary gland neoplasm. Tumefaction is constituted of ductal articulations coated with mono-layered epithelial cells and a cytological resemblance to normal striated ducts. Striated duct adenoma may recapitulates normal configuration of salivary ducts. Striated duct adenoma was initially scripted by Dardick wherein the neoplasm was designated as ‘ductal adenomas with no visible myoepithelial cells’ in 1996.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"52 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113970446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：